SEATTLE (TheStreet) -- Dendreon (DNDN) reported weaker-than-expected Provenge sales of $49.6 million in the second quarter and withdrew revenue guidance for the remainder of the year due to reimbursement issues. Provenge sales in the quarter totaled $49.6 million included a nearly $2 million reserve for chargebacks and rebates, but still fell far below Wall Street's expectations that ranged from $55 million to $60 million. "We believe the market potential for Provenge is substantial, and the primary issue affecting the dynamics of our launch is the reimbursement knowledge around Provenge," said Dendreon CEO Mitch Gold, in a statement. As a result, Dendreon withdrew its previous guidance calling for 2011 Provenge sales in the range of $350 million to $400 million and now expects "modest" quarter over quarter revenue growth for the remainder of this year. To cope with lower Provenge sales, Dendreon will cut costs, including firing an undisclosed number of employees, the company said. Wall Street has paid close attention to Dendreon's commercial launch of Provenge since the first-of-its-kind prostate cancer cancer immunotherapy received FDA approval last year. But Provenge's performance is receiving even more attention today from investors wanting to see demand for Provenge take off now that Dendreon's manufacturing supply constraints are lifting. At the end of June, FDA approved a second Provenge manufacturing facility. At the same time, the government agency overseeing Medicare announced a favorable coverage decision for the drug and granted Dendreon a temporary code to speed reimbursement payments to doctors. The latter is particularly important given Provenge's $93,000 price tag. But what can only be described as a shocking turn of events, Dendreon confessed Wednesday that reimbursement concerns and issues are dragging on Provenge sales. A third Provenge manufacturing facility is under construction with FDA approval expected on August 28. Dendreon narrowed its second quarter net loss to $114.6 million, or 79 cents a share from a net loss of $142.6 million, or $1.04 a share in the June 2010 quarter. Looking further ahead, Provenge could see increased competition from other companies developing drugs on their own, including Johnson & Johnson (JNJ) , Medivation (MDVN) and Exelixis (EXEL) . Dendreon shares closed Wednesday up 86 cents to $35.84 but the stock was halted ahead of the surprisingly negative second quarter earnings announcement
In the twisted world that is Wall Street, news of layoffs could be the stock's saving grace. The company is still growing revenue and capping costs as it tries to "recover" from a 49.6MM quarter. If you were going to hold Dendreon through 2011-2012, then there's no need to panic. Dendreon will continue to grow revenue, Atlanta should be approved by end of August, and management should work on resolving and refining the reimbursement issues.